84,022 Immatics N.V. $IMTX Shares Sold by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. trimmed its holdings in Immatics N.V. (NASDAQ:IMTX) by 1.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,422,780 shares of the company’s stock after selling 84,022 shares during the quarter. Immatics comprises approximately 0.4% of Jefferies Financial Group Inc.’s portfolio, making the stock its 28th biggest position. Jefferies Financial Group Inc.’s holdings in Immatics were worth $56,392,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in shares of Immatics by 5.5% during the 2nd quarter. Wellington Management Group LLP now owns 1,647,852 shares of the company’s stock worth $16,693,000 after buying an additional 85,960 shares during the last quarter. Troluce Capital Advisors LLC purchased a new position in shares of Immatics in the 1st quarter valued at $2,460,000. Alps Advisors Inc. grew its position in shares of Immatics by 46.2% in the 3rd quarter. Alps Advisors Inc. now owns 198,239 shares of the company’s stock valued at $1,741,000 after buying an additional 62,640 shares during the last quarter. Tidal Investments LLC grew its position in shares of Immatics by 0.7% in the 2nd quarter. Tidal Investments LLC now owns 171,499 shares of the company’s stock valued at $1,737,000 after buying an additional 1,110 shares during the last quarter. Finally, SummitTX Capital L.P. raised its stake in Immatics by 56.1% during the 1st quarter. SummitTX Capital L.P. now owns 151,112 shares of the company’s stock worth $1,487,000 after acquiring an additional 54,328 shares in the last quarter. 64.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. Jefferies Financial Group set a $17.00 price target on shares of Immatics in a research report on Tuesday, August 25th. Wall Street Zen downgraded shares of Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, October 31st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immatics in a report on Friday, September 18th. Mizuho set a $21.00 target price on Immatics in a research report on Thursday, October 29th. Finally, Stifel Nicolaus began coverage on Immatics in a report on Tuesday, October 13th. They issued a “buy” rating and a $15.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.

Immatics Price Performance

Immatics stock opened at $6.69 on Thursday. The business has a 50 day simple moving average of $7.83 and a 200-day simple moving average of $9.45. Immatics N.V. has a 12 month low of $6.09 and a 12 month high of $12.41. The stock has a market capitalization of $914.46 million, a PE ratio of -3.43 and a beta of 1.38.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.07). The firm had revenue of $7.84 million for the quarter, compared to analyst estimates of $12.18 million. Immatics had a negative return on equity of 52.27% and a negative net margin of 533.26%. As a group, equities research analysts anticipate that Immatics N.V. will post -1.99 EPS for the current year.

Insiders Place Their Bets

In other Immatics news, Director Perceptive Advisors Llc bought 863,060 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were bought at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the transaction, the director owned 11,246,516 shares of the company’s stock, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.30% of the company’s stock.

About Immatics

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells. Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.